Compare Harmony Gold Mining Co. (HMY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Inovio Pharmaceuticals Inc — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while Inovio Pharmaceuticals Inc trades at $1.13 (market cap $112.19M). The key difference: Harmony Gold Mining Co. is far larger — about 89.3× Inovio Pharmaceuticals Inc's market cap, and Harmony Gold Mining Co. pays a 4.63% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| HMY | INO | |
|---|---|---|
Market Cap | $10.02B | $112.19M |
Volume | 3,643,683 | 3,201,278 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $2.65 |
52-Week Low | $13.32 | $0.66 |
Typical Hold Time | 45 Days | 43 Days |
Enterprise Value | $10.07B | $83.51M |
Dividend Yield | 4.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.88, up 2.37% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 29.57% net income margin and robust revenue growth, climbing from $42.6B in 2022 to $73.9B in 2025. Recent earnings have been mixed, with two beats and two misses in the last four quarters. Analyst sentiment is cautious, with a consensus leaning heavily toward Hold.
The outlook for HMY is balanced; its low P/E of 6.02 and expansion into copper production offer value, but bearish technicals and high hold ratings suggest near-term volatility. Key risks include execution of growth projects and commodity price fluctuations, while institutional interest remains a supportive factor.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
